RP-HPLC KULLANILARAK TASARIM YAKLAŞIMI YOLUYLA KOMBİNE FORMÜLASYONDA BULUNAN LAMİVUDİN VE EFFAVİRENZ’İN TAYİNİNE YÖNELİK YÖNTEM GELİŞTİRİLMESİ

Year 2023, , 625 - 636, 20.05.2023

Bhagavan Rajesh Babu Koppisetty , Prof. Y. Rajendra Prasad , Krishna Manjari Pawar Amgoth , Srinivasa Rao Yarraguntla , Vasudha Dadı , Hemant Kumar Tatapudı

https://doi.org/10.33483/jfpau.1181816

Cited By: 1

Abstract

Amaç: Kombinasyon formülasyonunda lamivudin (LAM) ve effavirenzin (EVZ) ölçümü için karmaşık olmayan ve güvenilir bir sıvı kromatografik yaklaşım önerilmiştir.
Gereç ve Yöntem: Deney tasarımı (DoE), RP-HPLC yönteminin çok değişkenli optimizasyonu için deneysel koşulları ayarlamak üzere kullanıldı. RP-HPLC yönteminin çok değişkenli optimizasyonu, deneysel koşullar, deney tasarımı (DoE) kullanılarak gerçekleştirildi. Kritik yöntem parametreleri bir risk değerlendirmesi ile belirlendi. Matematiksel modeller üç bağımsız değişken kullanılarak oluşturulmuştur: asetonitril yüzdesi, metanol yüzdesi ve tampon pH'ı. Bu bağımsız öğelerin etkileri, yanıt yüzeyi metodolojisini analiz etmek için kullanılan merkezi bileşik tasarım (CCD) kullanılarak ayrıntılı bir şekilde incelenmiştir.
Sonuç ve Tartışma: LAM ve EVZ tutma süresi ve çözünürlüğü, arzu edilebilirlik işlevi kullanılarak aynı anda optimize edildi. Her biri 40:20:40 v/v oranlarındaki asetonitril, metanol ve fosfat tamponu (pH 7.0), 215 nm'lik bir dalga boyunda meydana gelen algılama ile kontur diyagramından optimize edilmiş ve beklenen verilerde kullanılmıştır. Her iki farmasötik maddenin yüksek çözünürlükte ve 6 dakikanın altında çalışma süresiyle temel ayrımı, bu ideal koşullar altında gerçekleştirildi. Doğrulanmış test parametreleri, ICH önerilerini izledi. Sonuç olarak, bulgular Tasarıma Göre Kalite metodolojisinin LAM ve EVZ'nin eş zamanlı ölçümü için RP-HPLC tekniğini optimize etmek üzere başarılı bir şekilde kullanılabileceğini göstermiştir.

Keywords

Effavirenz, lamivudin, merkezi kompozit tasarım, RP-HPLC, tasarıma göre kalite

UTILITY OF QUALITY BY DESIGN APPROACH IN RP-HPLC METHOD DEVELOPMENT FOR QUANTIFICATION OF LAMIVUDINE AND EFFAVIRENZ IN COMBINATION FORMULATION

Abstract

Objective: For the measurement of lamivudine(LAM) and effavirenz (EVZ) in combination formulation, an uncomplicated and reliable liquid chromatographic approach has been proposed.
Material and Method: The design of experiments (DoE) was used to set up the experimental conditions for the multivariate optimization of the RP-HPLC method. The crucial method parameters were determined by a risk assessment. The mathematical models were created using three independent variables: percentage of acetonitrile, percentage of methanol, and buffer pH. The impacts of these independent elements were thoroughly investigated using the central composite design (CCD), which was utilized to analyze the response surface methodology.
Result and Discussion: The LAM and EVZ retention time and resolution were both concurrently optimized using the desirability function. Acetonitrile, methanol, and phosphate buffer (pH 7.0) in the proportions of 40:20:40 v/v each were used in the optimized and anticipated data from the contour diagram, with detection occurring at a wavelength of 215 nm. Baseline separation of both pharmaceuticals with high resolution and a run time of under 6 minutes was accomplished under these ideal conditions. The validated test parameters followed ICH recommendations. As a consequence, the findings demonstrated that the Quality by Design methodology could be successfully used to optimize the RP-HPLC technique for the concurrent quantification of LAM and EVZ.

Keywords

Central composite design, effavirenz, lamivudine, quality by design, RP-HPLC

References

• 1. Bahrami, G., Mirzaeei, S., Kiani, A., Mohammadi, B. (2005). High-performance liquid chromatographic determination of lamivudine in human serum using liquid-liquid extraction; application to pharmacokinetic studies. Journal of Chromatography B, 823(2), 213-217. [CrossRef]
• 2. Checa, A., Oliver, R., Hernandez-Cassou, S., Saurina, J. (2008). Reversed-phase liquid chromatographic method with spectrophotometric detection for the determination of antiretroviral drugs. Analytica Chimica Acta, 616, 85-94. [CrossRef]
• 3. Kano, E.K., Reis Serra E.E., Koono, M., Andrade, S.S. (2005). Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies. International Journal of Pharmaceutics, 297, 73-79. [CrossRef]
• 4. Nalini, C.N., Nithya, A., Afreen, A., Banu, A.A. (2018). Analytical methods for determination of lamivudine and their applicability in biological studies. Research Journal of Pharmacy and Technology, 11(11), 5166-5172. [CrossRef]
• 5. Mogatle, S., Kanfer , I. (2009). Rapid method for the quantitative determination of efavirenz in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 49, 1308-1312. [CrossRef]
• 6. Matthews, C.Z., Woolf, E.J., Mazenko, R.S., Haddix-Wiener, H. (2000). Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis, 28, 925-934. [CrossRef]
• 7. Nacenta, M.S., Pua, Y.L., Cortes, L.F.L., Mallolas, J. (2001). Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B., 763, 53-59. [CrossRef]
• 8. More, S., Tandulwadkar, S., Nikam, A., Rathore, A. (2013). Separation and determination of lamivudine, tenofovir disoproxil fumarate and efavirenz in tablet dosage form by thin-layer chromatographicdensitometric method. Journal of Planar Chromatography-Modern TLC, 26(1), 78-85. [CrossRef]
• 9. Bhavsar, D.S., Patel, B.N., Patel, C.N. (2012). RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form. Pharmacutical Methods, 3(2), 73-78. [CrossRef]
• 10. Anandakumar, K., Abirami, G., Murugan, S., Ashok, B. (2013). RP-HPLC method for simultaneous estimation of lamivudine, tenofovir disoproxil fumarate and efavirenz in tablet formulation. Journal of Analytical Chemistry, 68, 815-821. [CrossRef]
• 11. Godela, R., Kammari, V., Gummadi, S., Beda, D. (2021). Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method. Future Journal of Pharmaceutical Science, 7, 94. [CrossRef]
• 12. Kumar, T.H., Prajna C.K.K., Rao, K.V., Rao, Y.S. (2019). RP-HPLC method for estimation of tramadol hydrochloride and paracetamol ın pharmaceutical formulation. GSC Biological and Pharmaceutical Sciences, 8(1), 89-97. [CrossRef]
• 13. Vidyadhara, S., Rao, Y.S., Ramu, A., Sasidhar, R.L. (2013). Method development and validation for the simultaneous estimation of cinitapride and pantoprazole in solid dosage forms by RP-HPLC. Oriental Journal of Chemistry, 29(3), 1213. [CrossRef]
• 14. Nagamani, P., Manjunath, S.Y., Kumar, T.H. (2020). Development and validation of RP-HPLC method for estimation of amlodipine besylate and celecoxib in pharmaceutical formulation. Journal of Drug Delivery and Therapeutics, 10(6), 31-36. [CrossRef]
• 15. Lakshmi Teja, G., Srinivasa Rao, Y., Vara Prasada Rao, K., Hemant Kumar, T. (2015). RP-HPLC method for estimation of atomoxetine hydrochloride in bulk and pharmaceutical dosage form. Research Journal of Pharmaceutical Biological and Chemical Sciences 6(2), 1208-1214.
• 16. ICH. (R1), (2005). Validation of analytical procedures: text and methodology. Vol. Q2.